



S1 Fig. Overall survival (OS) of *de novo* stage IV patients and relapsed patients (A). OS (B) and progression-free survival (C) according to the number of cycles of docetaxel treatment. OS according to the participation in a clinical trial (D). OS in *de novo* stage IV patients, trastuzumab-non-exposed relapsed patients, and trastuzumab-exposed relapsed patients (E). MBC, metastatic breast cancer.